investtemp
9月前
Pharma Cos., FDA Debate 'Same Drug' In Orphan Drug Case
By Ali Sullivan · Listen to article
Law360 (May 10, 2024, 9:26 PM EDT) -- Two pharmaceutical companies and the U.S. Food and Drug Administration faced off in D.C. federal court Friday over allegations that the federal agency wrongly approved a treatment that rivals Jazz Pharma's narcolepsy drug despite Jazz's exclusivity rights under the Orphan Drug Act.
U.S. District Judge Amit P. Mehta did not rule from the bench following the two-and-a-half hour summary judgment hearing in Washington, D.C., but his questioning signaled that his decision could hinge on the meaning of the term "same drug" in the Orphan Drug Act.
Jazz Pharmaceuticals Inc., which sued the FDA in June 2023, is seeking summary judgment on claims that the FDA unlawfully approved a rival narcolepsy treatment in violation of Jazz's exclusivity rights under the ODA. The exclusivity rights, Jazz says, bar the FDA from approving a new drug application "for the same drug for the same disease or condition" until its seven-year period of orphan-drug exclusivity expires.
Jazz argues that two drugs are the same when they are marketed for the same condition and have the same "active moiety" — that is, "the portion of the drug substance responsible for pharmacological activity." And because rival drug Lumryz has the same active moiety as Jazz's Xywav treatment, the FDA acted unlawfully when it approved Lumryz in 2023, Jazz contends.
But Lumryz developer Avadel CNS Pharmaceuticals LLC, which intervened in the case and has filed its own bid for summary judgment, argues that the drugs aren't the same at all. Although they are both oxybate drugs aimed at helping patients get a better sleep, patients taking Lumryz only need one dose at bedtime, while patients taking Xywav must take a second dose midway through the night, according to Avadel.
The once-nightly dosing means Lumryz is clinically superior, making it a different drug, Avedal has argued.
"If you apply the clinical superiority test, you find we are clinically superior," Avedal's attorney Philip Perry of Latham & Watkins LLP told the judge on Friday.
During the hearing, Judge Mehta pressed attorneys for the three parties on Congress' 2017 changes to the Orphan Drug Act.
The change came after then-U.S. District Judge Ketanji Brown Jackson's 2014 ruling in Depomed Inc. v. U.S. Department of Health and Human Services. The judge ruled that drugmaker Depomed Inc. didn't have to prove that its drug Gralise was clinically superior to a similar medicine manufactured by Pfizer Inc. called Neurontin in order to obtain seven years of orphan-drug marketing exclusivity.
However, Congress in 2017 passed legislation that said drugmakers must show their orphan drug has clinical superiority to get the sought-after exclusivity period. And, among other things, lawmakers edited the law to block approval of the "same drug," rather than "such drug," during the exclusivity period.
While Judge Mehta remarked that there's "not a lick of legislative history" on the record indicating Congress' motives for changes, U.S. Department of Justice attorney Noah T. Katzen said it would be quite the coincidence for lawmakers to pass legislation authorizing exactly what the D.C. federal court said the FDA could not do.
The FDA has asserted in court filings that its regulations have long defined "same drug" to exclude clinically superior drugs. Congress using the same language creates an "irresistible assumption" that lawmakers intended for the term to align with the existing FDA definition, Katzen argued.
Counsel for Jazz declined to comment following the hearing, and counsel for Avedal did not immediately return a request for comment.
Jazz is represented by Kwaku A. Akowuah, Sean C. Griffin, Tobias S. Loss-Eaton and Peter A. Bruland of Sidley Austin LLP.
The FDA is represented by Noah T. Katzen and Isaac C. Belfer of the U.S. Department of Justice's Civil Division's Consumer Protection Branch.
Avedal is represented by Philip J. Perry, Andrew D. Prins, John R. Manthei and Nicholas L. Schlossman of Latham & Watkins LLP.
The case is Jazz Pharmaceuticals Inc. v. Xavier Becerra et al., case number 1:23-cv-01819, in the U.S. District Court for the District of Columbia.
--Additional reporting by Adam Lidgett and Hailey Konnath. Editing by Dave Trumbore.
LongRun8
2年前
Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision
Source: GlobeNewswire Inc.?
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Pre-Launch Activities Importation Requests (PLAIR) for LUMRYZ.
Through its PLAIR, Avadel is authorized to import unapproved drug product into the U.S. ahead of anticipated final approval of the tentatively approved LUMRYZ NDA, to prepare for market launch. By importing LUMRYZ into the U.S. before anticipated final approval, Avadel is able to further shorten the time to product availability following a final approval decision by the FDA.
“The granting of our PLAIR request by the FDA followed the submission of our amendment requesting a final approval decision for LUMRYZ. The approval to import LUMRYZ comes at an important time for Avadel as the availability of commercial supply allows us to further shorten the timeline between a potential approval and being able to provide LUMRYZ to patients,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. “We remain committed to working collaboratively with FDA to bring LUMRYZ to people living with narcolepsy.”
About LUMRYZ
LUMRYZ is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
In March 2020, Avadel completed the REST-ON study, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, to assess the efficacy and safety of LUMRYZ in patients with narcolepsy. Among the three co-primary endpoints, LUMRYZ demonstrated statistically significant and clinically meaningful results in EDS, the clinician’s overall assessment of the patient’s functioning, and reduction in cataplexy attacks, for all three evaluated doses when compared to placebo.
In January 2018, the U.S. Food and Drug Administration (FDA) granted LUMRYZ Orphan Drug Designation for the treatment of narcolepsy based on the plausible hypothesis that LUMRYZ may be safer than the twice-nightly formulation of sodium oxybate already approved by the FDA due to the ramifications associated with the dosing regimen of that product. LUMRYZ is currently under review by the FDA.
On July 18, 2022, the FDA tentatively approved the LUMRYZ NDA for the treatment of cataplexy or EDS in adults with narcolepsy. Avadel submitted a minor amendment to the FDA on March 1, 2023, requesting final approval of LUMRYZ. This minor amendment submission occurred shortly after the delisting of the REMS Patent from FDA’s Orange Book by Jazz Pharmaceuticals in response to the unanimous 3-0 panel decision by the United States Court of Appeals for the Federal Circuit on February 24, affirming the previous ruling from the United States District Court for the Federal District of Delaware, ordering Jazz to do so.
Avadel is currently evaluating the long-term safety and tolerability of LUMRYZ in the open-label RESTORE clinical study. For more information, visit: www.restore-narcolepsy-study.com.
About PLAIR
A PLAIR allows for applicants with a pending NDA, ANDA, or CDER-regulated BLA nearing an FDA application decision to request permission to import an unapproved finished dosage form drug product for reconditioning in the form of approval. FDA’s granting of a PLAIR does not represent an implicit or explicit statement of the approvability of the NDA, ANDA, or CDER-regulated BLA. Rather, PLAIR facilitates the process for importing unapproved finished dosage form products to prepare for market launch based on anticipated approval of the pending application.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. For more information, please visit www.avadel.com.
Cautionary Disclosure Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, expectations regarding the FDA’s potential final approval of LUMRYZ, including the timing of thereof; the anticipated time savings between a potential approval and commercial launch of LUMRYZ attributable to the FDA’s grant of the PLAIR; the Company’s preparation for launch of LUMRYZ (if approved); and the market acceptance of LUMRYZ (if approved). In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions, and the negatives thereof (if applicable).
The Company’s forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, the Company’s business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of the company’s business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in the Company’s forward-looking statements include the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission (SEC) on March 16, 2022, and subsequent SEC filings.
Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.
Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687
Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688
?
?
?
Hot Features
プレミアム
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Monksdream
11月前
TheFinalCD
3年前
Just-Keep-Trying
3年前
willlbone
3年前
green maschine
3年前
ClayTrader
5年前
davidsson10
6年前
ALL-IN888
6年前
